Most oncology drugs turn things off—Alligator Bioscience prefers to turn things on, specifically, the immune system, by way of stimulation with CD40 and 4-1BB agonists. In this podcast, Alligator CEO, Søren Bregenholt, discusses the latest clinical data for lead anti-CD40 asset, mitazalimab, as well as two distinct 4-1BB agonists in development. Additionally, he answers the critical question: How did you tame the toxicity of these signaling molecules when so many others have failed?
Podden och tillhörande omslagsbild på den här sidan tillhör LifeSci Partners.com. Innehållet i podden är skapat av LifeSci Partners.com och inte av, eller tillsammans med, Poddtoppen.
